Boundless Bio Inc. (BOLD) has shared an update.
Boundless Bio, Inc. has initiated a stock option repricing for select employees and executive officers to $3.56 per share, aligning with the company’s closing stock price on August 19, 2024. This move aims to retain and incentivize key personnel while avoiding additional equity grants and cash expenses. Repriced options are subject to service conditions until a designated “Premium End Date,” with specific terms for early exercise or termination. Notably, top executives have had a significant number of their options adjusted, maintaining the original terms except for the new, lowered exercise price.
For an in-depth examination of BOLD stock, go to TipRanks’ Stock Analysis page.
